Fresenius Kabi USA LLC: FDA Warning Letter, Sep 22, 2026

Status: Unknown as of Oct 16, 2026. Warning letters are informal and advisory, not final agency action. Original on FDA.gov.

Company
Fresenius Kabi USA LLC (as published by FDA)
Letter date
Sep 22, 2026
Posted
Sep 29, 2026
Office
Center for Drug Evaluation and Research (CDER)
Subject
“CGMP/Finished Pharmaceuticals/Adulterated”
Response
None posted by FDA as of last check
Close-out
None posted by FDA as of last check
Source
FDA.gov · retrieved Oct 16, 2026

Get new FDA warning letters by email. One digest a week, free.

Double opt-in: we email you a link to confirm. One-click unsubscribe in every email. You must be at least 18. See our Privacy policy.

Need it same day for your suppliers? Reserve a founding Pro seat.

Topics: Drug manufacturing (CGMP)

Text above is quoted or paraphrased from FDA.

Something wrong or out of date? Request a correction. We review correction requests within 5 business days.

← All letters